Diffusion tensor imaging
A biomarker for mild traumatic brain injury?
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The most common yet most controversial neurologic injury is mild traumatic brain injury (mTBI), which may have an annual incidence rate as high as 653/100,000.1 Most mTBI cases have a positive outcome; the controversy exists in whether lasting sequelae occur. Typically, the neurologic examination is negative other than subtle cognitive complaints and subjective symptoms (e.g., headache, dizziness), as is conventional brain imaging. After head injury, the absence of definitive findings and a Glasgow Coma Score at or above 13 is the standard that defines mTBI.
There has been an active search for biomarkers of mTBI for clinical or research purposes. Conventional neuroimaging may reveal contusion or hemorrhage—referred to as complicated mTBI—however, such findings occur in fewer than 20% of mTBI cases evaluated in an emergency department,2 minimizing its utility. CNS-related serum proteins have been identified in mTBI, but have proven unsuccessful as biomarkers. Variables such as loss of consciousness (LOC) and duration of posttraumatic amnesia (PTA) are important in assessing mTBI and its outcome, but outside of a research setting, LOC and PTA are difficult to identify and verify. The above-mentioned physical or neurocognitive symptoms associated with mTBI are nondescript, so they too lack specificity as objective markers. Without an accurate …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Alert Me
Recommended articles
-
Articles
Diffusion tensor imaging of acute mild traumatic brain injury in adolescentsE. A. Wilde, S. R. McCauley, J. V. Hunter et al.Neurology, March 17, 2008 -
Articles
Diffusion tensor MRI assesses corticospinal tract damage in ALSC.M. Ellis, A. Simmons, D.K. Jones et al.Neurology, September 01, 1999 -
Article
White matter correlates of cognitive dysfunction after mild traumatic brain injuryIain D. Croall, Christopher J.A. Cowie, Jiabao He et al.Neurology, July 16, 2014 -
Research Article
White Matter Disruption in Pediatric Traumatic Brain InjuryResults From ENIGMA Pediatric Moderate to Severe Traumatic Brain InjuryEmily L. Dennis, Karen Caeyenberghs, Kristen R. Hoskinson et al.Neurology, May 28, 2021